CEACAM8 Recombinant Monoclonal Antibody

CEACAM8, also known as CD66b, is a glycosylphosphatidylinositol-anchored member of the carcinoembryonic antigen family that plays a significant role in neutrophil activation and adhesion processes. As a marker predominantly expressed on granulocytes, CEACAM8 has become an important target for researchers investigating innate immune responses, inflammatory conditions, and neutrophil biology. Its involvement in cell-cell interactions and signal transduction makes it a valuable focus for immunology studies exploring leukocyte function and disease mechanisms.

This recombinant monoclonal antibody, clone 24H12, offers the consistency and reliability that demanding experimental workflows require. Produced using recombinant technology in rabbit host, this antibody provides sequence-defined specificity against a synthesized peptide derived from human CEACAM8, ensuring reproducible results across experiments and eliminating the lot-to-lot variability that can complicate long-term research projects. The affinity-chromatography purification process delivers a high-purity reagent suitable for sensitive detection applications.

Validation studies demonstrate robust performance in Western blot analysis across multiple human cell lines, including JK, HepG2, HT29, THP-1, and A549 lysates. The observed band at approximately 100 kDa aligns with the higher predicted molecular weight range, reflecting the extensive glycosylation characteristic of CEACAM family members. This antibody is also validated for ELISA and flow cytometry applications, with recommended dilutions of 1:50-1:200 for flow cytometry, providing flexibility for researchers working across different experimental platforms.

For investigators studying neutrophil biology, inflammatory responses, or immune cell characterization, this CEACAM8 antibody delivers the specificity and reproducibility essential for generating publication-quality data.